5 ways Election Day could impact pharma

By Brian Buntz | October 30, 2020

4. If Trump is reelected, but Democrats control Congress

In this scenario, Trump may refuse to collaborate with Democrats. Despite prior calls for bipartisanship, Trump has frequently demonized his enemies.

But it is also possible that Trump and Democrats could forge an unlikely healthcare alliance. “Trump is pretty far left when it comes to drug pricing,” Caliendo concluded. Trump’s drug-pricing executive orders are rooted more in populism than prior Republican presidents. And there could be a political penalty for vetoing legislation that promises to help improve drug access to millions of Americans. After all, nearly 30% of Americans are not taking medicines as prescribed owing to high costs, according to the Kaiser Family Foundation.

Next >>

Pages: 1 2 3 4 5 6

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at [email protected].